Health Affairs, 28, no. 1 (2009): w161-w164 (Published online 16 December 2008) doi: 10.1377/hlthaff.28.1.w161 © 2009 by Project HOPE	New Online   Senate Health Reform Bill   Rewarding Providers   Public Option Policy Brief   Health Reform & Abortion   Delivery System Reform

This Article Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when Comments are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Scherer, F.M. Search for Related Content PubMed PubMed Citation Articles by Scherer, F.M. Related Collections Health Reform International Issues Pharmaceuticals Chronic Care Health Spending Consumer Issues Related Articles

Web Exclusives

PERSPECTIVE

Price Controls And Global Pharmaceutical Progress

This Perspective reviews critically the work on price control impacts by Darius Lakdawalla and colleagues. It argues that the innovation elasticity of 3.0 emphasized by the authors is too high, exaggerating the long-run costs of price controls. It argues, too, that the drugs chosen for the authors’ analysis are neither the most therapeutically innovative candidates nor those whose development is most likely to be discouraged by price controls.

                      What's this?

Related Articles

• Neeraj Sood, Han de Vries, Italo Gutierrez, Darius N. Lakdawalla, and Dana P. Goldman
  The Effect Of Regulation On Pharmaceutical Revenues: Experience In Nineteen Countries
  Health Affairs, January/February 2009; 28(1): w125-w137.
  [Abstract] [Full Text] [Figures Only] [PDF] [Appendices][Table Of Contents]
   
  
• Darius N. Lakdawalla, Dana P. Goldman, Pierre-Carl Michaud, Neeraj Sood, Robert Lempert, Ze Cong, Han de Vries, and Italo Gutierrez
  U.S. Pharmaceutical Policy In A Global Marketplace
  Health Affairs, January/February 2009; 28(1): w138-w150.
  [Abstract] [Full Text] [Figures Only] [PDF] [Appendix]
   
  
• Murray Aitken, Ernst R. Berndt, and David M. Cutler
  Prescription Drug Spending Trends In The United States: Looking Beyond The Turning Point
  Health Affairs, January/February 2009; 28(1): w151-w160.
  [Abstract] [Full Text] [Figures Only] [PDF]
   
  
• Arjun Jayadev and Joseph Stiglitz
  Two Ideas To Increase Innovation And Reduce Pharmaceutical Costs And Prices
  Health Affairs, January/February 2009; 28(1): w165-w168.
  [Abstract] [Full Text] [PDF]